Alopecia Areata Treatment: Which Pipeline Therapy Will Steal the Spotlight?
What is Alopecia Areata?
There is currently no cure for alopecia and no FDA-approved therapies. As a result, off-label medication therapies totally dominate the alopecia areata treatment industry. There are several alopecia areata treatment options available, depending on the level of hair loss and age. Treatment's basic purpose is to stop the immune system attack or stimulate hair regeneration. This can be helpful, particularly for persons with milder types of disease.
Furthermore, around 700,000 persons in the United States have alopecia areata, with just under half of these patients having entire scalp or total body baldness. Alopecia areata is thus the second most frequent type of hair loss in the United States, trailing only pattern baldness or a receding hairline.
Despite declining trends in the global burden of alopecia areata, the incidence and disability-adjusted life-years rates in low-income countries and Western Sub-Saharan Africa continue to rise. Alopecia areata affects 2% of the population and is a major contributor to psychiatric illnesses such as depression, anxiety, and mental health suffering.
FDA approves new systemic alopecia areata treatment
Due to the scarcity of alopecia areata treatment options, many people with the condition turned to wigs and false eyelashes. People suffering from alopecia areata encounter tremendous difficulties because the disorder is highly stigmatizing. OLUMIANT (baricitinib) oral tablets were authorized by the Food and Drug Administration on June 13, 2022, to treat adult patients with severe alopecia areata. The treatment intends to treat the complete body rather than the specific area being developed by Eli Lilly & Company and Incyte Corporation. There were no FDA-approved alopecia areata treatments before the approval of Olumiant. This is a big step forward for both persons with alopecia areata and the professionals who have been campaigning for them.
Upcoming potential therapies for alopecia areata treatment
Concert Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Pfizer, Legacy Healthcare, AnaptysBio, Reistone Biopharma, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, and others are currently developing novel alopecia areata therapies. Currently, the pipeline for alopecia areata drugs includes CTP-543, Jaktinib, Ritlecitinib, LH-8, ANB030, SHR0302, and others.
Changing alopecia areata treatment trajectory
The US FDA chose alopecia areata as one of eight new disease areas to focus on during its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The PFDDI's purpose is to incorporate patient viewpoints into product development earlier. Extensive alopecia areata posed a significant treatment hurdle due to the lack of FDA-approved systemic therapies for the illness. At first, prospective alopecia areata treatments included topical corticosteroids, tacrolimus, cryotherapy, minoxidil, anthralin, or ultraviolet light A coupled with oral psoralens (PUVA), all of which lacked convincing evidence for consistent success in alopecia areata.
Coverage policies must ensure access to FDA-approved alopecia areata treatments
It is critical to broadening policymakers' and payers' understanding of alopecia areata; seeing alopecia areata as merely "hair loss" lessens the pain of many individuals living with this disease and minimizes the relevance of providing coverage for alopecia areata therapy. The FDA classifies alopecia areata as a chronic autoimmune condition with a "debilitating emotional and psychological impact on patients that extends beyond hair loss."
Future perspective in the alopecia areata treatment
Alopecia areata treatments have progressed over the years from broad and nonspecific alopecia areata therapy to those that are now more targeted and rationally chosen. This was accomplished by collaboration and communication between physicians and fundamental scientists, resulting in the investigation and comprehension of the specific pathophysiology of alopecia areata. Olumiant's approval by the US Food and Medicine Administration is a significant step forward because no drug has ever been approved for alopecia areata treatment. Pfizer's ritlecitinib and Concert Pharmaceuticals' CTP-543 are two more important oral JAK inhibitors in alopecia areata (deuruxolitinib). AnaptysBio, which is researching its anti-PD-1 monoclonal antibody rosnilimab in a placebo-controlled Phase II trial, presents an alternative method in this arena.
Numerous innovative treatments are undergoing clinical trials for the treatment of alopecia areata, underlining the potential change in alopecia areata clinical practice, which is now lacking. With these recent advancements, the therapeutic arena of alopecia areata treatments is now becoming more exciting. Alopecia areata will be added to the growing list of dermatologic illnesses that will be treated with mechanism-targeted medications, transforming the face of alopecia areata treatment.
Related Reports:
Diagnostic Imaging Equipment Market
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Sialidosis Market
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ventricular Assist Devices (VAD) Market
Ventricular Assist Devices (VAD) Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027
Latest Reports by DelveInsight
Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market
For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Also, take a glance at the Blogs by DelveInsight:
Comments
Post a Comment